Foye's principles of medicinal chemistry.
Foye's principles of medicinal chemistry.
Principles of medicinal chemistry
- Seventh edition. International edition / edited by Thomas L. Lemke, PhD, David A. Williams, Phd ; associate editors, Victoria F. Roche, PhD, S. William Zito, PhD.
- Philadelphia, PA : Wolters Kluwer/Lippincott Williams & Wilkins, [2013]
- xviii, 1500 pages : illustrations (black and white) ; 29 cm
Includes Internet access. Previous edition: published as by Thomas L. Lemke. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2008.
Includes bibliographical references and index.
History and evolution of medicinal chemistry -- Part I: Principles of drug discovery -- 1.Drug discovery from natural products. A. Douglas Kinghorn -- 2.Drug design and relationship of functional groups to pharmacologic activity. Robin M. Zavod and James J. Knittel -- 3.Physicochemical and biopharmaceutical properties of drug substances and pharmacokintics. Sunil S. Jambhekar -- 4.Drug metabolism. Davd A. Williams -- 5.Membrane drug transporters. Marilyn E. Morris and Bridget L. Morse -- 6.Pharmaceutical biotechnology. Tanaji T. Talele, Marc Gillespie, and Vijaya L. Korlipara -- 7.Receptors as targets for drug discovery. David A. Johnson and Timothy J. Maher -- 8.Drug discovery through enzyme inhibition. Stephen Kerr -- Part II: Drug receptors affecting neurotransmitters and enzymes as catalytic receptors -- 9.Drugs affecitng cholinergic neurotransmission. E. Kim Fifer -- 10.Andrenergic receptors and drugs affecting anrenergic neurotransmission. Robert K. Griffith -- 11.Serotonin receptors and drugs affecting serotonergic neurotransmission. Richard A. Glennon and Malgorzata Dukat -- 12.Amino acid neurotransmiters in the central nervous systems. Timothy J. Maher -- Part III.Pharmacodynamic agents. Section I: Drugs used to reat neuromuscular disorders: antiparkinsonian and spasmolytic agents. Raymond G. Booth - 14.Antipsychotic and anxiolytic drugs. Raymond G. Booth -- 15.Sedative-hynoptics. Nader H. Moniri -- 16.Anesthetic agents: general and local anesthetics. Timothy J. Maher -- 17.Antiseizure drugs. Barbara Leduc -- 18.Antidepressants. David A. Williams -- 19.Hallucinogenics, stimulants, and related drugs of abuse and their therapeutic potentials. Ricard A. Glennon -- 20.Central analgesics. David A. Williams, Victoria F. Roche, and Edward B. Roche -- Section 2: Drugs affecting the cardiovascular system -- 21.Cardiac agents: cardiac glycosides, antianginal, and antiarrhythmic drugs. Ahmed S. Mehanna -- 22.Diurectics. Peter J. Harvison and Gary O. Rankin -- -- 23.Agents affecting the renin-angiotensin pathway and calcium blockers. Marc Harrold -- 23.Central and peripheral sympatholytics and vasodilators. David A. Williams -- 25.Antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis. Marc Harrold -- 26.Antithrombotics, thrombolytics, antiplatelets and coagulants. Matthias C. Lu -- Section 3: Drugs affecting the hormonal systmes -- 27.Insulin and drugs used to reat diabetes. S. William Zito -- 28.Adrenocorticoids. Duan D. Miller, Robert W. Brueggmeier, and James D. Dalton -- 29.Thyroid function and thyroid drugs. Ali R. Banijamali -- 30.Calcium homeostasis. Robin M. Zavod -- Section 4: Drugs affecting the immune system -- 31.Nonsteroidal anti-inlammatory drugs. Ronal Borne, Mark Levi, and Norman Wilson -- 32.Antihistamines and related antiallergic and antiucler agents. Wndell L. Nelson -- Section 5: Chemotherapeutic agents -- 33.Antibiotics and antimicrobial agents. Elmer J. Gentry -- 34.Antiparasitic agents. Thomas L. Lemke -- 35.Antifungal agents. Thomas L. Lemke -- 37.Cancer and chemotherapy. Victoria F. Roche -- 38.Antiviral agents and proteases inhibitors. Patrick M. Woster -- Part IV.Disease state management -- 39.Asthma and chronic obstructive pulmonary disease. S. William Zito -- 40.Men\'s health. Duane D. Miller, Robert W. Brueggmeier, and James T. Dalton -- 41.Women\'s health. Robin M. Zavod -- 43.Nutrition and obesity. Thomas L. Lemke and David A. Williams.
This edition places emphasis on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems.
9781451175721 (hbk.) : £52.00 9781451175721 (hardback) : Đ52.00
Pharmaceutical chemistry.
Health and Wellbeing.
Pharmacology
Pharmaceutical chemistry & technology
RS403 / .P75 2013
616.0756 FOY
Includes Internet access. Previous edition: published as by Thomas L. Lemke. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2008.
Includes bibliographical references and index.
History and evolution of medicinal chemistry -- Part I: Principles of drug discovery -- 1.Drug discovery from natural products. A. Douglas Kinghorn -- 2.Drug design and relationship of functional groups to pharmacologic activity. Robin M. Zavod and James J. Knittel -- 3.Physicochemical and biopharmaceutical properties of drug substances and pharmacokintics. Sunil S. Jambhekar -- 4.Drug metabolism. Davd A. Williams -- 5.Membrane drug transporters. Marilyn E. Morris and Bridget L. Morse -- 6.Pharmaceutical biotechnology. Tanaji T. Talele, Marc Gillespie, and Vijaya L. Korlipara -- 7.Receptors as targets for drug discovery. David A. Johnson and Timothy J. Maher -- 8.Drug discovery through enzyme inhibition. Stephen Kerr -- Part II: Drug receptors affecting neurotransmitters and enzymes as catalytic receptors -- 9.Drugs affecitng cholinergic neurotransmission. E. Kim Fifer -- 10.Andrenergic receptors and drugs affecting anrenergic neurotransmission. Robert K. Griffith -- 11.Serotonin receptors and drugs affecting serotonergic neurotransmission. Richard A. Glennon and Malgorzata Dukat -- 12.Amino acid neurotransmiters in the central nervous systems. Timothy J. Maher -- Part III.Pharmacodynamic agents. Section I: Drugs used to reat neuromuscular disorders: antiparkinsonian and spasmolytic agents. Raymond G. Booth - 14.Antipsychotic and anxiolytic drugs. Raymond G. Booth -- 15.Sedative-hynoptics. Nader H. Moniri -- 16.Anesthetic agents: general and local anesthetics. Timothy J. Maher -- 17.Antiseizure drugs. Barbara Leduc -- 18.Antidepressants. David A. Williams -- 19.Hallucinogenics, stimulants, and related drugs of abuse and their therapeutic potentials. Ricard A. Glennon -- 20.Central analgesics. David A. Williams, Victoria F. Roche, and Edward B. Roche -- Section 2: Drugs affecting the cardiovascular system -- 21.Cardiac agents: cardiac glycosides, antianginal, and antiarrhythmic drugs. Ahmed S. Mehanna -- 22.Diurectics. Peter J. Harvison and Gary O. Rankin -- -- 23.Agents affecting the renin-angiotensin pathway and calcium blockers. Marc Harrold -- 23.Central and peripheral sympatholytics and vasodilators. David A. Williams -- 25.Antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis. Marc Harrold -- 26.Antithrombotics, thrombolytics, antiplatelets and coagulants. Matthias C. Lu -- Section 3: Drugs affecting the hormonal systmes -- 27.Insulin and drugs used to reat diabetes. S. William Zito -- 28.Adrenocorticoids. Duan D. Miller, Robert W. Brueggmeier, and James D. Dalton -- 29.Thyroid function and thyroid drugs. Ali R. Banijamali -- 30.Calcium homeostasis. Robin M. Zavod -- Section 4: Drugs affecting the immune system -- 31.Nonsteroidal anti-inlammatory drugs. Ronal Borne, Mark Levi, and Norman Wilson -- 32.Antihistamines and related antiallergic and antiucler agents. Wndell L. Nelson -- Section 5: Chemotherapeutic agents -- 33.Antibiotics and antimicrobial agents. Elmer J. Gentry -- 34.Antiparasitic agents. Thomas L. Lemke -- 35.Antifungal agents. Thomas L. Lemke -- 37.Cancer and chemotherapy. Victoria F. Roche -- 38.Antiviral agents and proteases inhibitors. Patrick M. Woster -- Part IV.Disease state management -- 39.Asthma and chronic obstructive pulmonary disease. S. William Zito -- 40.Men\'s health. Duane D. Miller, Robert W. Brueggmeier, and James T. Dalton -- 41.Women\'s health. Robin M. Zavod -- 43.Nutrition and obesity. Thomas L. Lemke and David A. Williams.
This edition places emphasis on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems.
9781451175721 (hbk.) : £52.00 9781451175721 (hardback) : Đ52.00
Pharmaceutical chemistry.
Health and Wellbeing.
Pharmacology
Pharmaceutical chemistry & technology
RS403 / .P75 2013
616.0756 FOY